Arvinas (ARVN) Revenue & Revenue Breakdown
Arvinas Revenue Highlights
Latest Revenue (Y)
$262.60M
Latest Revenue (Q)
$15.60M
Main Segment (Y)
License
Arvinas Revenue by Period
Arvinas Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $262.60M | -0.30% |
| 2024-12-31 | $263.40M | 235.54% |
| 2023-12-31 | $78.50M | -40.26% |
| 2022-12-31 | $131.40M | 145.15% |
| 2021-12-31 | $53.60M | 106.95% |
| 2020-12-31 | $25.90M | -39.73% |
| 2019-12-31 | $42.98M | 200.03% |
| 2018-12-31 | $14.32M | 89.00% |
| 2017-12-31 | $7.58M | 13.64% |
| 2016-12-31 | $6.67M | - |
Arvinas generated $262.60M in revenue during NA 2025, up -0.30% compared to the previous quarter, and up 1013.90% compared to the same period a year ago.
Arvinas Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $15.60M | 64.21% |
| 2025-12-31 | $9.50M | -77.33% |
| 2025-09-30 | $41.90M | 87.05% |
| 2025-06-30 | $22.40M | -88.14% |
| 2025-03-31 | $188.80M | 218.92% |
| 2024-12-31 | $59.20M | -42.19% |
| 2024-09-30 | $102.40M | 33.86% |
| 2024-06-30 | $76.50M | 202.37% |
| 2024-03-31 | $25.30M | -158.70% |
| 2023-12-31 | $-43.10M | -224.57% |
| 2023-09-30 | $34.60M | -36.51% |
| 2023-06-30 | $54.50M | 67.69% |
| 2023-03-31 | $32.50M | -14.47% |
| 2022-12-31 | $38.00M | 14.46% |
| 2022-09-30 | $33.20M | -1.78% |
| 2022-06-30 | $33.80M | 27.55% |
| 2022-03-31 | $26.50M | 0.76% |
| 2021-12-31 | $26.30M | 182.80% |
| 2021-09-30 | $9.30M | 69.09% |
| 2021-06-30 | $5.50M | - |
| 2021-03-31 | $5.50M | 148.01% |
| 2020-12-31 | $2.22M | -70.81% |
| 2020-09-30 | $7.60M | 32.17% |
| 2020-06-30 | $5.75M | -7.88% |
| 2020-03-31 | $6.24M | 27.51% |
| 2019-12-31 | $4.89M | -83.72% |
| 2019-09-30 | $30.05M | 648.17% |
| 2019-06-30 | $4.02M | - |
| 2019-03-31 | $4.02M | 16.75% |
| 2018-12-31 | $3.44M | 1.92% |
| 2018-09-30 | $3.38M | -0.72% |
| 2018-06-30 | $3.40M | -17.25% |
| 2018-03-31 | $4.11M | 59.73% |
| 2017-12-31 | $2.57M | 54.13% |
| 2017-09-30 | $1.67M | - |
| 2017-06-30 | $1.67M | - |
| 2017-03-31 | $1.67M | - |
Arvinas generated $15.60M in revenue during Q1 2026, up 64.21% compared to the previous quarter, and up 26.35% compared to the same period a year ago.
Arvinas Revenue Breakdown
Arvinas Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| License | $130.00M | $130.00M |
Latest
Arvinas's latest annual revenue breakdown by segment (product or service), as of Dec 25: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $15.60M | - | - | - | - | - | - | - |
| License | - | - | $130.00M | $130.00M | $130.00M | - | $130.00M | $130.00M |
Latest
Arvinas's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Reportable Segment (100.00%).
Arvinas Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IOVA | Iovance Biotherapeutics | $263.50M | $71.43M |
| ARVN | Arvinas | $262.60M | $15.60M |
| GERN | Geron | $183.88M | $47.23M |
| DNA | Ginkgo Bioworks | $170.16M | - |
| DAWN | Day One Biopharmaceuticals | $158.18M | $39.80M |
| VALN | Valneva SE | $153.70M | $32.75M |
| MGTX | MeiraGTx | $33.28M | $293.00K |
| REPL | Replimune Group | - | - |
| ERAS | Erasca | - | - |
| AVBP | ArriVent BioPharma | - | - |